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Abstract
Background: The objective of this study is to evaluate the efficiency and safety of carbon nanoparticles (CNPs) for
harvesting lymph nodes (LNs) in cases of advanced gastric cancer (AGC).
Methods: Patients with previously untreated resectable AGC were eligible for inclusion in this study. All patients
were randomly allocated to two subgroups. In the experimental group, 1.0 mL of CNP was injected into the
subserosa of the stomach around the tumor before gastrectomy with D2 dissection. The same procedure was
performed directly without any coloring material in the control arm. Following surgery, LNs were harvested, colored
LNs were counted, and the diameters were measured by the investigator and pathologist.
Results: Thirty patients were enrolled in the study. We observed no serious adverse effects related to CNP injection.
The rate of stained LNs was 46.6 %. The mean number of harvested LNs was larger in the experimental than in the
control group (38.33 vs 28.27, p = 0.041). A smaller diameter of LNs was recorded in the experimental arm (3.32 vs
4.30 mm, p = 0.023). In addition, we developed a model for predicting the total number of LNs based on the data
from CNP-stained LNs and metastatic LNs (MLNs).
Conclusions: CNP is a safe material. Surgeons could harvest more LNs in patients with AGC. The harvest of an increased
number of smaller diameters of LNs may be beneficial. Further study is warranted to demonstrate the model’s practicality.
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Background
Although gastric cancer decreased from being the most
common cancer in 1975 to being the fifth most common
neoplasm in 2012, it remains the third leading cause of
cancer death worldwide, contributing to 723,000 deaths
annually [1, 2]. Screening and broad-based awareness of
the disease has improved the identification rates of early-
stage cancers and superior survival. However, compared
with some developed countries, such as Japan, a majority
of patients are diagnosed with advanced gastric cancer
(AGC) in China, which presents a treatment challenge.
Gastrectomy with D2 lymph node (LN) dissection is the
standard treatment for AGC in Asia because of the sur-
vival benefit and low complication rate [3, 4]. A similar
study result was published recently with data from west-
ern countries [5]. There was no controversy on the neces-
sity of dissecting lymph nodes. In the light of guidelines,
histopathological examination of at least 15 regional
lymph nodes is necessary to accurately assign the N
category for gastric carcinoma. Intriguingly, undoubtedly
reflecting the contribution of stage migration and dissect-
ing more metastatic LNs, representing the quality of the
* Correspondence: jiafuji2000@163.com
The abstract of this paper has been accepted for poster presentation to the
2015 Gastrointestinal Cancers Symposium.
†Equal contributors
1Key Laboratory of Carcinogenesis and Translational Research Ministry of
Education, Department of Gastrointestinal Surgery, Peking University Cancer
Hospital and Institute, Fu-Cheng-Lu Street, Beijing, People’s Republic of China
4Department of Gastrointestinal Surgery, Peking University Cancer Hospital
and Institute, Beijing, People’s Republic of China
Full list of author information is available at the end of the article
© 2016 Li et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. World Journal of Surgical Oncology  (2016) 14:88 
DOI 10.1186/s12957-016-0835-3
operation, overall survival (OS) improved incrementally
with higher LN counts [6–8]. Based on these results, we
attempted to develop a method to obtain more LNs. In
other studies, lymphatic tracers, including dye materials,
have been used to meet this need [9]. Carbon nanoparti-
cles (CNPs) are a practicable material for harvesting
lymph nodes in our department.
CNPs with a mean size of 150 nm can be taken up se-
lectively by the lymphatics after injection into the tissue.
The draining regional lymph nodes are thereby colored
black, which may provide guidance to the surgeon dur-
ing lymph node dissection and help harvest lymph nodes
after surgery, especially smaller LNs. However, there is
insufficient evidence to justify its efficacy for those pur-
poses. Therefore, we carried out a prospective random-
ized controlled trial on lymph node vital staining for LN
dissection and harvesting in AGC.
Methods
Patients
Thirty-two 20- to 80-year-old resectable AGC patients from
December 2013 to June 2014 diagnosed by pathological
biopsy, staged by computed tomography (CT) and endo-
scopic ultrasonography (EUS), who had no prior treat-
ment, were chosen for this trial. All patients were
diagnosed by a multi-disciplinary team and provided writ-
ten informed consent before surgery. The exclusion cri-
teria were as follows: R0 resection was not achieved by
gastrectomy with D2 lymphadenectomy according to
Japanese gastric cancer treatment guidelines 2010 (ver.3)
[10], having an allergic reaction, being pregnant, or being
proved to be stage T1 or M1 after surgery. Two patients
were excluded; one was pathologically diagnosed as in the
T1 stage and the other was cytology positive by a laparo-
scopic approach. Thus, 30 patients were analyzed. Figure 1
shows the trial scheme.
CNP staining, open gastrectomy with D2 dissection, and
lymph node harvesting
The patients were enrolled before the operation accord-
ing to a randomized table generated by the statistician
(Yan Zhang). All were randomly allocated to two sub-
groups. In the experimental group, 1.0 mL of CNP (car-
bon nanoparticles suspension injection, 1 mL/50 mg,
Fig. 1 Trial scheme
Li et al. World Journal of Surgical Oncology  (2016) 14:88 Page 2 of 8
Chongqing, China) was injected into the subserosa of the
stomach at five points around the tumor on average
(0.2 mL in each cardinal point adjacent to the lesion,
Fig. 2a) 10 min before open gastrectomy with D2 dissec-
tion. In distal gastrectomy (DG, Fig. 2c), a free proximal
margin of at least 4 cm was necessary according to the
gastric cancer treatment guidelines of the Japanese Gastric
Cancer Association (ver. 3). En bloc excision was done in
lymph nodes of station nos. 1, 3, 4sb, 4d, 5, 6, 7, 8, 9, 11p,
12a, and 14v if metastasis was highly suspected in no. 6. In
addition, nos. 2, 11d, and 10 were resected in total gastrec-
tomy (TG, Fig. 2b). The same gastrectomy was performed
directly without any coloring material in the control arm.
Pictures or videos of the surgery were evaluated by the en-
tire team in our department after the operation to ensure
that a standard D2 gastrectomy was performed.
After surgery, the investigator (Sheng Ao) harvested
the lymph nodes with the pathologists (10 min for each
patient’s specimens) and simultaneously counted the col-
ored LNs. The tissues were fixed in formalin solution
and embedded in paraffin for histological examination
with H&E staining. Then, the diameters of each LN were
measured.
This study was designed as a single-center prospective
clinical trial. The procedure was approved by the Ethics
Committee of Beijing Cancer Hospital. The study protocol
was released on ClinicalTrials.gov (ID: NCT02123407).
Study design
The primary outcome measure was to calculate the
number of harvested LNs. The second outcome meas-
ure was the diameter of the harvested LNs, which was
aimed to obtain the maximum dimension to reflect the
degree of difficulty of picking up LNs. In addition, op-
eration time, bleeding, and complications were com-
pared between the two groups to confirm the safety
of CNP.
Respectively, the average number of lymph nodes we
harvested in advanced gastric cancer cases without CNP
was 28.76 ± 1.14. The sample size was set at 30 (15 each
group) based on the assumption that the expected num-
ber of LNs should increase by at least one, with a two-
sided alpha of 5 % and at least 90 % power. The planned
duration of accrual was 7 months. All statistical analyses
were conducted with SPSS 17.0 software.
Fig. 2 a Carbon nanoparticles were injected into the subserosa of the stomach around the tumor; the arrows show the injection sites. b D2
dissection performed in total gastrectomy; spleen-preserving station no. 10 was resected. SV splenic vessels, PGA posterior gastric artery. c D2
dissection performed in distal gastrectomy; portions of dissected LNs are shown. CHA common hepatic artery, LGA left gastric artery, LGV left
gastric vein, RGV right gastric vessels, DS duodenal stump.
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Results
The background factors, perioperative outcomes, patho-
logical findings, and operation-related outcomes were
shown in Table 1. Age, BMI, location, surgery, and
pathological stage of tumor were not significantly differ-
ent in the two groups, nor were the operation time,
bleeding, and complications. No allergies and no toxic
reactions or side effects from the injection of CNP were
recorded in any case.
The harvested LNs of every patient and every station
were described in Fig. 3a, c, where significant differences
could be found among station nos. 1 and 3 in the two
groups. The rate of stained LNs was 46.6 % in the ex-
perimental arm (Fig. 3b). The mean number of har-
vested LNs was larger in the experimental than in the
control group (38.33 vs 28.27, p = 0.041, Table 2). No
significant differences were found on the presence of
skip metastases among two groups (0/15 vs 0/15). The
ratio of the LN metastasis-positive patients was higher
than that of the control group (14/15 vs 7/15, p = 0.014),
while the number of metastatic LNs (MLNs) was not dif-
ferent (p = 0.126, Fig. 3b). To determine why the number
of LNs was larger with CNP treatment, additional
exploratory analyses of LN diameters were performed
(Fig. 4a). In the experimental group, pathological LN
diameters ranged from 0.5 to 15.0 mm, with a mean of
3.32 mm. Not unexpectedly, a mean diameter of
4.30 mm with a range from 0.5 to 20.0 mm was re-
corded in the control group (Table 3). A smaller diam-
eter in station nos. 1 and 3 could be observed in the
experimental arm, although this was not statistically sig-
nificant (Fig. 4b, c).
We attempted to design a model for predicting the
total number of LNs based on the data of CNP-staining
LNs and MLNs by utilizing statistical linear regression
model method (Table 4). This model proved to be the
following linear equation:
Y ¼ 11:628þ 1:062X1þ 1:126X2
Discussion
Lymphatic tracers, such as methylene blue, indocyanine
green, and an intraoperative radiation technique with a
gamma probe, had been widely used as guidance for
lymph node searching and dissection for some years
[11, 12]. It was initially confirmed that lymphatic tracers
were useful to improve OS by harvesting more LNs. In
fact, both surgeons and pathologists have trouble harvest-
ing LN because of their busy workload, especially in
China, which has the highest number of people in the
world. Furthermore, no ideal materials were found due to
the limitation of their staining efficiency, the relatively
complicated lymphatic flow of the gastric system, radi-
ation injury, and expense. Carbon particles, which are
convenient, inexpensive, and widely available in general
hospitals, have been used by others for LN staining and
were shown to be safe [13, 14]. Similarly, in our study, no
CNP-related side effects occurred, there was no extra
bleeding, the length of surgery was not extended, and no
extra complications were observed.
This prospective randomized controlled trial was mainly
designed to test the efficiency of CNP. In the design re-
search process, injection method was considered. Because
lymphatic vessels are connected to each other by a com-
municating branch in the gastric wall which expands ver-
tically, many researchers held the view that injection
methods were equally efficient in lymph node staining in
AGC [15, 16]. We obtained similar results in a preliminary
experiment; thus, we selected to perform subserosal dye
injection, which is an easier and more effective method
during open surgery. Our staining rate was 46.6 %, some-
what lower than the rate reported in Japanese studies
about early gastric cancer [17]. There might be two rea-
sons for this difference. First, more lymphatic vessels were
blocked by the tumor in AGC. On the other hand, more
LNs from the N2 station were dissected in AGC for the






Sex Male 10 (9.5) 9 (9.5) 0.705
Female 5 (5.5) 6 (5.5)
Age (years) >70 2 (1.5) 1 (1.5)
50–70 11 (9.5) 8 (9.5) 0.380
<50 2 (4.0) 6 (4.0)
BMI 25.45 ± 3.60 23.80 ± 2.44 0.155
Lauren type Intestinal 3 (3.0) 3 (3.0)
Nonintestinal 12 (12.0) 12 (12.0) 1.000
Location Upper 5 (4.5) 4 (4.5)
Middle 2 (3.0) 4 (3.0) 0.788
Lower 8 (7.5) 7 (7.5)
Surgery DSG 7 (7.0) 7 (7.0)
TG 8 (8.0) 8 (8.0) 1.000
Stage IB 0 (1.0) 2 (1.0)
II 5 (6.0) 7 (6.0) 0.242
III 10 (8.0) 6 (8.0)
Operation
time (min)
214.7 ± 42.9 212.9 ± 55.7 0.922
Bleeding (mL) 110.0 ± 63.2 98.7 ± 66.2 0.635
Complication Yes 5 (4.0) 3 (4.0)
No 10 (11.0) 12 (11.0) 0.682
*Analyzed by Student’s t test or the χ2 test
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development of gastric surgery, which were more difficult
to stain because of distance and lymphatic vessel complex
structure.
Obviously, more LNs were harvested in patients with
CNP staining (38.33 vs 28.27). The difference agreed
with Catarci’s finding using CH40 (a type of dye mater-
ial) [18]. Nevertheless, we obtained a larger number of
LNs and better standard gastrectomy with D2 dissection.
However, subgroup analysis showed no more MLNs
were harvested in the experimental group, which might
be due to sample size. On the other hand, the higher ra-
tio of the LN metastasis-positive patients than that of
the control group indicated that CNP could help im-
prove the discovery rate of metastatic LN, but more
study are needed to prove the result.
To explore why we could harvest more LNs with CNP,
we measured the maximum diameter of each LN for a
satisfactory outcome. Only we offer the data in detail.
From the point of view of the operation, en bloc excision
of LNs could be complete because they were distin-
guished more easily from adipose tissues if colored
black. In addition, some small LNs (<2.0 mm) would not
Fig. 3 a Harvested LNs from every patient. b Total number of harvested LNs and metastatic LNs in the experimental and control groups.
c Harvested LNs from every station
Table 2 Mean number of harvested LNs
Number Means of lymph nodes p value
Experimental group 15 38.33
Control group 15 28.27 0.041
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be left (Fig. 5) in the case of micrometastases, which could
have a very important influence on N staging and treat-
ment strategies. We also realized that the greatest differ-
ence happened in station nos. 1 and 3. Although not
statistically significant, the clinical value should not be ig-
nored because more small LNs were harvested. Mean-
while, bias in our subgroup analyses was unavoidable so
Fig. 4 a Mean diameters of LNs in each patient. b Mean diameter of LNs in station no. 3. c Mean diameter of LNs in station no. 1
Table 3 Mean diameter of harvested LNs
Number Means of diameter (mm) p value
Experimental group 15 3.32
Control group 15 4.30 0.023
Table 4 Model for predicting total number of LNs
Model β SE t p
Constanta 11.628 7.839 1.483 0.164
CNP-staining LNs 1.062 0.329 3.223 0.007
Metastatic LNs 2.373 1.126 0.475 0.035
R square 0.537
Sample size 15
Dependent variable: number of lymph nodes (Y); predictors: constant,
CNP-staining LNs (X1), metastatic LNs (X2)
aGender, age, BMI, location, surgery, operation time, bleeding, diameter, and
pathological stage were included
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that more studies should be designed to provide such data
of every LN station.
Finally, we set up a forecasting model to evaluate the
quality of the operation if CNP was used. Since the im-
portance of statistics was noticed, more and more scien-
tists, such as Gretschel [19], have combined it with
medicine to solve clinical problems. To some extent, our
model may help the surgeons review their work of re-
moving LNs to improve their surgical skills. For in-
stance, surgeons could compare their resected LNs to
the predicting number calculated with this model to
evaluate the quality of operation. However, this work
should be tested in more cases.
Conclusions
Our results indicated that CNP was a safe material and
that surgeons could harvest more LNs with it in cases of
AGC, which might benefit from the harvest of an in-
creased number of smaller LNs. The model we built in
this study could play a role in evaluating the surgeon’s
capacity and their training. However, further study is
needed to prove its practicality.
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